Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04762771 Suspended - Covid19 Clinical Trials

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

Colheart-19
Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label unblinded, randomized study to treat hospitalized covid-19 patients with colchicine plus current care (per institution treating physicians) vs. current care per institution treating physicians alone (the control arm)

NCT ID: NCT04613271 Suspended - Covid19 Clinical Trials

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

FVR
Start date: October 15, 2020
Phase: Phase 3
Study type: Interventional

The benefit of the research is to provide information regarding the efficacy and safety of Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a reference for policy recommendations regarding the use of Favipiravir as an antiviral drug for the treatment of Covid-19.

NCT ID: NCT04602884 Suspended - Covid19 Clinical Trials

Early Detection of COVID-19 Using Breath Analysis

COVID-19
Start date: September 22, 2020
Phase: N/A
Study type: Interventional

EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY

NCT ID: NCT04510038 Suspended - Covid19 Clinical Trials

Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury

COLHEART-19
Start date: January 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Open-label randomized study comparing the current standard of care treatment of Covid-19 in hospitalized patients with evidence of cardiac injury vs. a group of the same type of patients treated with colchicine plus current standard of care.

NCT ID: NCT04477902 Suspended - Covid19 Clinical Trials

Long-Term Experience and Health Effects of COVID-19

Start date: July 1, 2020
Phase:
Study type: Observational

The purpose of this study is to gain on-going COVID-19 feedback/data to drive timely action locally and nationally in order to mitigate transmission. Data will be deidentified and consolidated to create a large national longitudinal database.

NCT ID: NCT04357028 Suspended - Covid19 Clinical Trials

Measles Vaccine in HCW

MV-COVID19
Start date: July 13, 2020
Phase: Phase 3
Study type: Interventional

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

NCT ID: NCT04341870 Suspended - COVID19 Clinical Trials

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO

CORIMUNO-VIRO
Start date: April 11, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047). Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation. All patients will receive standard of care along with randomized investigational treatments. Outcomes of included patients will be compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort treated with other immune modulators or standard of care.